12th week of 2011 patent applcation highlights part 27 |
Patent application number | Title | Published |
20110070166 | REDUCED DYE PROBES FOR THE DETECTION OF RADICAL OXYGEN SPECIES - Reduced dyes, such as hydrocyanines, deuterocyanines, and/or other deuterated dyes capable of detecting one or more reactive oxygen species are described herein. The reduced dyes exhibit little or no fluorescence due to the disrupted π conjugation. However, upon reaction with ROS, the reduced dyes are oxidized, regenerating the extended π conjugation and causing a substantial increase in fluorescence intensity. In many case, the oxidized dye is generally membrane impermeable. However, upon reduction, many of the reduced dyes are membrane permeable. Thus, reduced dyes can accumulate in cells and/or tissue to amplify the signal. Once inside the cell or tissue, the reduced dye is reoxidized upon reaction with ROS, and the oxidized dye again becomes membrane impermeable, trapping the dye within the cell. The reduced dyes can be used to image ROS, such as hydroxide radical and superoxide, in serum, cell cultures, tissue explants, and in vivo. | 2011-03-24 |
20110070167 | METHOD OF PREVENTING FIBRIN CLOTS IN PULMONARY TISSUE THROUGH THE USE OF AEROSOLIZED ANTICOAGULANTS - ATIII is a serine proteinase inhibitor (serpin) with anti-coagulant, anti-inflammatory, anti-proliferative and anti-angiogenic properties. The invention features methods of treating a subject having lung injury due to burns and smoke inhalation by administering a synergistic combination of antithrombin III and heparin through pulmonary delivery means. | 2011-03-24 |
20110070168 | MACROCYCLIC PEPTIDES AS INHIBITORS OF VIRAL REPLICATION - The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I | 2011-03-24 |
20110070169 | Effervescent Oral Fentanyl Dosage Form and Methods of Administering Fentanyl - Fentanyl-containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than known oral formulation and have advantages in terms of reduced cost and reduced side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa. | 2011-03-24 |
20110070170 | MANUFACTURE OF CHEWING GUM PRODUCT WITH RADIOFREQUENCY - The present invention features a process for making a chewing gum product including the steps of forming a powder blend containing a gum base into the desired shape of the chewing gum product and applying radiofrequency energy to the shape for a sufficient period of time to soften the gum base to fuse the shape into the chewing gum product. | 2011-03-24 |
20110070171 | 1-tert-Butylcyclohexanecarboxamide and uses thereof as cooling compounds - Described is a new cooling agent represented by Formula I and compositions with known coolers having cooling properties and the application of Formula I in foodstuffs and chewing gum: | 2011-03-24 |
20110070172 | Rebaudioside C and Its Stereoisomers as Natural Product Sweetness Enhancers - The present invention is directed to the use of rebaudioside C, or a stereoisomer thereof, for enhancing the sweet taste of carbohydrate sweeteners, such as sucrose and fructose. The present invention is also directed to consumables comprising a combination of a carbohydrate sweetener and rebaudioside C, or a stereoisomer thereof. | 2011-03-24 |
20110070173 | Oil-in-Water Type Emulsion Cosmetic Composition - This object of the invention is to provide an oil-in water emulsion cosmetic composition having fine sense of use and excellent dispersion stability, and does not occur twisting upon drying. | 2011-03-24 |
20110070174 | Benzoyl Peroxide and Sunscreen Agent Combination - A topical treatment for acne vulgaris comprising benzoyl peroxide and a sunscreen base in a stable compound and methods of manufacture and use. The finished compound being in cream, lotion, gel or other topical formulations. | 2011-03-24 |
20110070175 | USE OF ORGANOMODIFIED SILOXANE BLOCK COPOLYMERS AS CARE ACTIVE INGREDIENT FOR THE CARE OF HUMAN OR ANIMAL BODY PARTS - The present invention relates to the use of organomodified siloxane block copolymers as care active ingredient for the care of human or animal body parts. | 2011-03-24 |
20110070176 | METHOD FOR THE TREATMENT OF ACNE USING COMPOSITIONS COMPRISING 0.3% BY WEIGHT OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID - Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions. | 2011-03-24 |
20110070177 | COSMETIC PACKAGING AND APPLICATION COMBINATION FOR SHEAR-THINNING COMPOSITIONS - The present invention relates to a cosmetic packaging and application combination for making up and/or caring for keratinous substances including 1) a container holding a cosmetic composition in the water-in-oil emulsion form and characterized by a certain rheological profile and 2) an applicator. | 2011-03-24 |
20110070178 | Pre-Shave Preparation With Enhanced Lubricity - A pre-shave composition to lubricate skin, comprising at least one polyfluoroalkyl dimethicone polymer, a volatile component to serve as a carrier to the polyfluoroalkyl dimethicone polymer, and a suspending agent to suspend the polyfluoroalkyl dimethicone polymer in the volatile component. | 2011-03-24 |
20110070179 | CATIONIC ALCOHOLS AND USES THEREOF - Compositions are disclosed comprising novel fluorinated cationic alcohols in a cosmetically acceptable vehicle. The fluorinated compounds alter a surface property of the hair to provide hair conditioning, for example. In embodiments, the compounds have improved water solubility and deposition properties. | 2011-03-24 |
20110070180 | Compositions for Imparting Superhydrophobicity - Compositions and methods are disclosed for imparting water repellency to the hair. The compositions generally comprise a first hydrophobic particulate material having a coefficient of dynamic friction of 0.5 or greater in combination with a second hydrophobic particulate material having a coefficient of dynamic friction less than 0.5. | 2011-03-24 |
20110070181 | FRESHENING COMPOSITIONS COMPRISING MALODOR BINDING POLYMERS AND MALODOR COUNTERACTANTS - Freshening compositions comprising a malodor binding polymer, a malodor counteractant comprising at least one aliphatic aldehyde, and an aqueous carrier, wherein the composition is essentially free of any material that would soil or stain fabric; and methods thereof are provided. In some embodiments, the malodor binding polymer comprises a homopolymeric polyethylenimine having a molecular weight of about 1,000 to about 2,000,000. Such freshening compositions may be used to reduce malodor and/or microbes on inanimate surfaces or in the air. | 2011-03-24 |
20110070182 | FRESHENING COMPOSITIONS COMPRISING MALODOR BINDING POLYMERS - Freshening compositions comprising a malodor binding polymer and an aqueous carrier, wherein the composition is essentially free of any material that would soil or stain fabric; and methods thereof are provided. In some embodiments, the malodor binding polymer comprises a homopolymeric polyethylenimine having a molecular weight of about 1,000 to about 2,000,000. In some embodiments, the freshening composition includes a buffering agent providing a pH of about 6 to about 8. Such freshening compositions may be used to reduce malodor and/or microbes on inanimate surfaces or in the air. | 2011-03-24 |
20110070183 | CROSSLINKED POLYSILOXANES, A PROCESS FOR THEIR PREPARATION AND USE OF THE CROSSLINKED POLYSILOXANES IN EMULSIFIER SYSTEMS FOR WATER-IN-OIL EMULSIONS - The invention relates to crosslinked organopolysiloxanes which are linked by a polyether building block via the Si atoms, to emulsifier systems which have these crosslinked organopolysiloxanes, and also to cosmetic, dermatological or pharmaceutical formulations comprising a crosslinked organopolysiloxane or an emulsifier system comprising these. | 2011-03-24 |
20110070184 | METHODS AND COMPOSITIONS FOR TREATING ATHEROSCLEROSIS AND RELATED CONDIDTIONS - Described herein are methods for treating or preventing a atherosclerosis by inhibiting the activation or binding of macrophage migration inhibitory factor to CXCR2 and CXCR4. Such inhibition is achieved by administration of either a single agent or a combination of agents. Also described herein are agents that inhibit MIF-binding or MIF-activation of CXCR2 or CXCR4. Further described are pharmaceutical compositions comprising such agents and their use for treating or preventing atherosclerosis. | 2011-03-24 |
20110070185 | IDENTIFICATION OF ANTIGENIC PEPTIDES FROM MULTIPLE MYELOMA CELLS - Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines. | 2011-03-24 |
20110070186 | Methods of Treating Cancer Using Growth Factor Retargeted Endopeptidases - The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions. | 2011-03-24 |
20110070187 | Methods for the Preparation of HCV Polymerase Inhibitors - The present invention relates to methods and compounds useful in the preparation of compounds of the formula (I). | 2011-03-24 |
20110070188 | BAB TRIBLOCK POLYMERS HAVING IMPROVED RELEASE CHARACTERISTICS - Improved biodegradable and bioabsorbable BAB-block copolymers exhibiting reverse thermal gellation properties, and aqueous polymer compositions including the BAB-block copolymers, are provided. Methods of making the improved BAB-block copolymers and compositions including the same are also provided. | 2011-03-24 |
20110070189 | HETEROCYCLIC ANTIVIRAL COMPOUNDS - Compounds having the formula I wherein R | 2011-03-24 |
20110070190 | HETEROCYCLIC ANTIVIRAL COMPOUNDS - The invention discloses 1-N-substituted-6-(hetero)aryl-1H-thieno[3,2-d]pyrimidin-4-one derivatives of formula | 2011-03-24 |
20110070191 | T CELL RECEPTOR FUSIONS AND CONJUGATES AND METHODS OF USE THERE OF - Featured is T cell receptor complexes designed to redirect the immune system against various diseases. The T cell receptor complexes of the invention have been engineered to recognize target antigen in a functionally bispecific nature. Fusion protein complexes and protein conjugate complexes are comprised of high affinity antigen-specific TCR and biologically active proteins and/or effector molecules. Also featured is methods of production of T cell receptor fusion and conjugate complexes as well as therapeutic compositions for use of the complexes. | 2011-03-24 |
20110070192 | Method of preparation of novel nucleoside analogs and uses - Processes for the preparation of racemic and optically active nucleoside analogs of formula (A) are described. These compounds are useful as anti-infective agents, antisense therapeutic agents and hybridization assay probes. | 2011-03-24 |
20110070193 | Anti-Infective Agents and Uses Thereof - This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. | 2011-03-24 |
20110070194 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT - Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 2′ position of the nucleoside sugar is substituted with halogen and carbon substitutents. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections caused by both wild type and mutant strains of HCV. | 2011-03-24 |
20110070195 | USES OF SPATIAL CONFIGURATION TO MODULATE PROTEIN FUNCTION - This invention provides a set of methods for modulating protein spatial configuration. First, select the amino-acid codon for encoding the target protein according to host codon usage. Second, choose combinations which can modulate the spatial configuration and construct into different vectors which can transfect a series of hosts. Third, choose the vector promoter by monitoring a combination of base pairs after combining the code sequence of the promoter and the target protein. Finally, choose the appropriate expression host to express the target protein, refold and purify, measure the activity and spatial configuration. | 2011-03-24 |
20110070196 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2011-03-24 |
20110070197 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2011-03-24 |
20110070198 | Plant-based biocidal materials and systems - The present invention is directed to a method and a composition for producing and using a plant-based biocidal solution. The plant-based biocidal solution contains a bioactive material and a plant-based substance formed from the cellular material of a plant. The plant-based substance is capable of binding to the bioactive material. In some embodiments, the bioactive material is hydrogen peroxide. The hydrogen peroxide can be added exogenously or generated endogenously. In accordance with further embodiments, the plant-based biocidal solution can be applied to a target, thereby impairing the target. In some embodiments, the target can be a pathogen. In accordance with another embodiment, the plant-based substance of the plant-based biocidal solution can form a microscopic cluster, a complex, or an aggregate for providing sufficient bioactive material to overcome the defense mechanism of the target. | 2011-03-24 |
20110070199 | ADAPTABLE MODIFIED VIRUS VECTOR TO DELIVER RIBOSOMAL RIBONUCLEIC ACID COMBINED WITH MESSENGER RIBONUCLEIC ACID AS A MEDICAL TREATMENT DEVICE TO MANAGE DIABETES MELLITUS AND OTHER PROTEIN DEFICIENT DIEASES - Diabetes mellitus is a disease of elevated blood glucose, often directly related to a deficiency in insulin production or insulin receptor production. The innovative strategy of treatment described here utilizes modified viruses and virus-like vehicles to act as a transport mechanism to deliver ribosomal RNA molecules along with messenger RNA molecules to target cells in the body. Delivering to the Beta cells in the body the ribosomal RNA needed to assist ribosomes with the construction of insulin or insulin receptors along with messenger RNA will lead to enhanced production of biologically active insulin or insulin receptors by Beta cells as necessary, which will lead to correcting deficiencies in insulin or insulin receptors the result of which will help properly regulate blood glucose levels throughout the body utilizing innate regulatory mechanisms. | 2011-03-24 |
20110070200 | ABROGATING PROINFLAMMATORY CYTOKINE PRODUCTION DURING ONCOLYTIC REOVIRUS THERAPY - Provided herein are methods for treating a proliferative disorder in a subject comprising administering to the subject one or more reoviruses and one or more agents that modulate expression or activity of pro-inflammatory cytokines. For example, the agents may inhibit expression or activity of pro-inflammatory cytokines. | 2011-03-24 |
20110070201 | Mucosal or enteral administration of biologically active macromolecules - A method of systemically delivering a biologically active, recombinant biomolecule, in a biologically active form, to a subject in need thereof. , the method comprising, enterally or mucosally administering to the subject a therapeutically effective amount of plant cells expressing an exogenous biologically active recombinant biomolecule, thereby systemically delivering the biologically active recombinant biomolecule, in a biologically active form, to the subject. | 2011-03-24 |
20110070202 | Targeted delivery to the brain of magnetically labeled stem cells - Provided herein is a method of targeting stem cells to a specific region of the central nervous system of an individual in need of such treatment, comprising the steps of administering stem cells containing a superparamagnetic nanoparticles to said individual; and applying an external source of a magnetic field to the exterior of said individual's brain so as to advance and maneuver said stem cells. Also provided is a composition for targeting cells to a specific region of the central nervous system of an individual in need of such treatment, comprising stem cells containing a superparamagnetic nanoparticles. | 2011-03-24 |
20110070203 | MESENDODERM AND MESODERM CELL POPULATIONS - The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy. | 2011-03-24 |
20110070204 | MEDIUM FOR HANDLING AND STORING BIOLOGICAL TISSUES OF THE MUSCULOSKELETAL SYSTEM OUTSIDE AN ORGANISM - The present disclosure relates to a medium for handling, including storing, cultivating, coating, impregnating and/or preserving musculoskeletal tissues such as bone, cartilage, tendon, muscle, nerve, ligament, blood vessel, skin, fascia, bursa and joint capsule tissue or cells, wherein the medium is an aqueous solution comprising hyaluronan and a first saccharide, polyol, or combination thereof. Further disclosed are methods of handling musculoskeletal tissue or cells or preserving the viability of these tissues or cells using this medium as well as the preserved tissues or cells. | 2011-03-24 |
20110070205 | MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49 | 2011-03-24 |
20110070206 | METHODS OF APPLYING PHYSICAL STIMULI TO CELLS - We describe herein methods for applying physical stimuli to cells, including mesenchymal stem cells, in culture or in vivo. These methods can be applied in, and are expected to benefit subjects in, a great variety of circumstances that arise in the context of, for example, traumatic injury (including that induced by surgical procedures), wound healing (of the skin and other tissues), cancer therapies (e.g., chemotherapy or radiation therapy), tissue transplantation (e.g., bone marrow transplantation), and aging. More generally, the present methods apply where patients would benefit from an increase in the number of cells (e.g., stem cells) within a given tissue and, ex vivo, where it is desirable to increase the proliferation of cells (e.g., stem cells) for scientific study, inclusion in devices bearing cells (e.g., polymer or hydrogel-based implants), and administration to patients. | 2011-03-24 |
20110070207 | THERAPEUTIC COMPOSITION FOR ATOPIC DERMATITIS - A novel type of therapeutic agent, human mesenchymal stem cells, and a composition containing the same for the treatment of atopic dermatitis is disclosed. A method for the treatment of atopic dermatitis in patient is also disclosed. | 2011-03-24 |
20110070208 | HBV EPITOPE REACTIVE EXOGENOUS T CELL RECEPTOR (TCR) AND USES THEREOF - There is provided at least one isolated cell comprising at least one HBV epitope-reactive exogenous T cell receptor and/or fragment thereof, and methods for producing them. In particular, there is provided polynucleotides, constructs and vectors encoding at least one HBV epitope-reactive exogenous T cell receptor for use in the treatment of Hepatitis B Virus (HBV) and Hepatocellular Carcinoma (HCC). The invention further provides kits and methods of detection of HBV and HCC. | 2011-03-24 |
20110070209 | Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs - Acute and chronic diseases of the organs are treated in patients using a rational, multi-tier approach. A patient can be pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells or other cell therapy. The patient can be a fetus treated in utero or removed from the womb. The progress of treatment is monitored by ultrasound, MRI, CAT scan, cardiac echo, EEG, EKG, EMG or blood tests, with growth factor treatment and/or stem cell administration adjusted according to the results of the monitoring or clinical status of the patient. | 2011-03-24 |
20110070210 | SYSTEMS AND METHOD FOR HOMEOSTATIC BLOOD STATES - Decades of investigations were focused on finding “gold standard” for evaluation of plasma dilution and osmolality, blood loss evaluation and prediction of bleeding or transfusion induced changes in hematocrit and hemoglobin concentration. Addressing deficiencies of existing methods, the current invention created new combined mathematical-physiological model applicable to manually operated nomograms and software in medical monitors. The mathematical model HBS Trends is used in blood transfusion and infusion therapy nomogram—HBS Nomogram—which is based on blood hemoglobin concentration and hematocrit. It is also an easy and practical tool for recording and dynamical interpretation of plasma osmolality, blood hemoglobin concentration, hematocrit and mean corpuscular hemoglobin concentration. The HBS Nomogram is a practical system for organizing blood test results in a patient's medical records. It can be used alone or, in line with existing guidelines for infusion and transfusion therapy making them more practical, cost effective and time saving in decision making. | 2011-03-24 |
20110070211 | Methods of Treating Cancer Using Galanin Retargeted Endopepidases - The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions. | 2011-03-24 |
20110070212 | Methods of Treating Cancer Using Glucagon-Like Hormone Retargeted Endopeptidases - The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions. | 2011-03-24 |
20110070213 | DERMAL COMPOSITIONS CONTAINING COENZYME Q AS THE ACTIVE INGREDIENT - The present invention provides a composition for dermal application
| 2011-03-24 |
20110070214 | BACITRACIN METAL COMPLEXES USED AS BLEACH CATALYSTS - Bacitracin, bacitracin derivatives and other oligopeptides, alone or in the form of oligopeptide-metal ion complexes, are shown to be useful as bleach catalysts incorporated in washing and cleaning agents for the cleaning of soiled hard surfaces and textile fabrics. These catalysts may be used in conjunction with hydrogen peroxide or any alternate bleaching agent, or used simply in the presence of atmospheric oxygen to bleach stains. New and novel oligopeptides and their metal ion complexes are disclosed herein, along with methods for the cleaning of hard surfaces and textile fabrics with washing and cleaning agents incorporating these bleach catalysts. | 2011-03-24 |
20110070215 | METHODS OF TREATING CANCER USING NEUROTROPHIN RETARGETED ENDOPEPTIDASES - The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions. | 2011-03-24 |
20110070216 | THERAPEUTIC COMBINATION COMPRISING A PULMONARY SURFACTANT AND ANTIOXIDANT ENZYMES - Administration of an exogenous pulmonary surfactant in combination with antioxidant enzymes is effective for the prevention of bronchopulmonary dysplasia (BPD) and decreases the markers of pulmonary oxidative stress. | 2011-03-24 |
20110070217 | COMPOSITIONS AND METHODS FOR TREATING HIV INFECTION WITH CUPREDOXIN AND CYTOCHROME C - The present invention relates to cupredoxin, specifically | 2011-03-24 |
20110070218 | METHODS OF TREATING CANCER OF THE CENTRAL NERVOUS SYSTEM - A method of treating a cancer of the central nervous system in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of an agent which reduces blood glutamate levels and enhances brain to blood glutamate efflux to thereby treat the cancer of the central nervous system in the subject. | 2011-03-24 |
20110070219 | HIGH PRESSURE PROTEIN CRYSTALLIZATION - The present disclosure provides an effective method for the crystallization of proteins at high pressure. A preferential excluding agent, and optionally other reagents may be incorporated into the method. The method is applicable to substantially all proteins. | 2011-03-24 |
20110070220 | Immunomodulating gene therapy - The present invention relates, in general, to Pompe disease and, in particular, to a methods of treating Pompe disease and to compounds/constructs suitable for use in such methods. | 2011-03-24 |
20110070221 | GNAQ MUTATIONS IN MELANOMA - The present invention provides methods of detecting mutations in a Gnaq gene in a melanocytic neoplasm for diagnostic and prognostic purposes. The invention further provides methods of treating such melanocytic neoplasm by modulating the activity of the mutated Gnaq gene. | 2011-03-24 |
20110070222 | Therapeutic Modulation of Ocular Surface Lubrication - Provided herein are ophthalmically acceptable pharmaceutical compositions comprising a PRG4 inducing compound in combination with PRG4 (including a lubricant fragments, homologs, or isoforms thereof), and methods of using the same. The PRG4 inducing compound in the pharmaceutical composition of the present invention upregulates PRG4 expression and localization in the ocular surface for efficient surface boundary lubrication. In some instances, pharmaceutical compositions described herein are utilized for treating ophthalmic conditions, e.g., ocular boundary deficiency and symptoms associated therewith. | 2011-03-24 |
20110070223 | Uses of Lp-PLA2 in combination to assess coronary risk - This invention relates to a method for assessing risk of Coronary Vascular Disease (CVD). Specifically, it relates to utilizing risk assessment from both Lipoprotein Associated Phospholipase A2 (Lp-PLA2) and C-reactive protein (CRP) in combination. In addition the invention relates to a method for assessing risk of Coronary Vascular Disease (CVD) in a patient with low to normal Low Density Lipoprotein Cholesterol (LDL) levels utilizing both LDL and Lipoprotein Associated Phospholipase A2 (Lp-PLA2). Moreover, the invention relates to the use of risk associated with Lp-PLA2, CRP and LDL in combination and specific ranges thereof to predict Coronary Vascular Disease. | 2011-03-24 |
20110070224 | METHODS COMPOSITIONS AND DEVICES UTILIZING STINGING CELLS/CAPSULES FOR DELIVERING A THERAPEUTIC OR A COSMETIC AGENT INTO A TISSUE - A delivery device including at least one stinging capsule and methods of use are described. | 2011-03-24 |
20110070225 | Beta antibody parenteral formulation - The present invention relates to a stable pharmaceutical parenteral formulation of an antibody, antibody molecule, a mixture of antibodies and/or a mixture of antibody molecules against the amyloid-beta peptide (Abeta) and a process for the preparation. Furthermore, corresponding uses are described. | 2011-03-24 |
20110070226 | VARIABLE ANTIBODIES - The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VIII to levels between 40 and 95%. The present invention further discloses pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures. | 2011-03-24 |
20110070227 | Treatment of Autoimmune and Inflammatory Diseases - The invention relates to the treatment of autoimmune or inflammatory disorders with antibodies to CD22. In particular, the invention relates to the treatment of autoimmune or inflammatory disorders with epratuzumab with a new dosing regimen. More particularly, the invention relates to the treatment of SLE. | 2011-03-24 |
20110070228 | METHOD AND APPARATUS FOR AUTOMATED CELL TRANSFER THERAPY AND HAIR TRANSPLANTATION - Methods and apparatuses that selectively capture therapeutic cells associated with hair growth or development and their delivery to regions of hair loss. Cell capture and delivery is accomplished in part through the use of antibodies having binding sites specific to cell surface moieties characteristic of the therapeutic cells and having magnetic or paramagnetic features, which facilitates their immobilization to magnetizable rods that can be used to pierce the skin of the subject being treated for hair loss and the subsequent release of therapeutic cells to targeted sites beneath the epidermis. | 2011-03-24 |
20110070229 | Method of selecting a monoclonal antibody for administration - Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies. | 2011-03-24 |
20110070230 | Method and devices for identifying and treating a subject who has developed an anti-antibody response - Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies. | 2011-03-24 |
20110070231 | STABLE LIQUID PHARMACEUTICAL FORMULATION OF IGG ANTIBODIES - This invention is directed to a stable liquid pharmaceutical formulation comprising a high concentration, e.g. 50 mg/ml or more, of antibody in about 20-60 mM succinate buffer or 30-70 mM histidine buffer, having pH from about pH 5.5 to about pH 6.5, about 0.01-0.1% polysorbate, and a tonicity modifier that contributes to the isotonicity of the formulation. This liquid formulation is stable at refrigerated temperature (2-8° C.) for at least 1 year, and preferably 2 years. This liquid formulation is suitable for subcutaneous injection. The preferred antibodies include Daclizumab, a humanized anti-IL-2 receptor monoclonal antibody; HAIL-12, a humanized anti-IL-12 monoclonal antibody; HuEP5C7, a humanized anti-L selectin monoclonal antibody; and Flintozumab, a humanized anti-gamma interferon monoclonal antibody. | 2011-03-24 |
20110070232 | Combination Therapy with an Antitumor Alkaloid - The present invention relates to combinations of PM00104 with other anticancer drugs, and the use of these combinations in the treatment of cancer. | 2011-03-24 |
20110070233 | ACTRIIB ANTAGONISTS AND DOSING AND USES THEREOF - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma. Methods for dosing a patient with an ActRIIb antagonist are also provided. | 2011-03-24 |
20110070234 | NP1 ACTIVITY REGULATING ELEMENTS USEFUL FOR THE PRODUCTION OF DRUGS FOR THE TREATMENT OR PREVENTION OF HUMAN NEURODEGENERATIVE DISEASES, RESULTING DRUGS AND USE THEREOF - The invention relates to a series of compounds useful for the production of drugs or pharmaceutical compositions for the treatment or prevention of human neurological diseases, preferably neurodegenerative diseases, which inhibit the activity of the human NP1 protein which acts as an inducer of neurodegeneration and neural apoptosis. Said compounds include iRNA inhibitors of the gene expression of the NP1 gene and specific antibodies of the human NP1 protein, as well as peptides derived from same, which can be used in passive and active immunisation methods respectively against said diseases. | 2011-03-24 |
20110070235 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLUENZA - The present invention provides compositions, vaccines, and methods for diagnosing, treating, and preventing influenza infection using a combination of antibodies raised against the influenza hemagglutinin and the matrix 2 ectodomain polypeptides. | 2011-03-24 |
20110070236 | USE OF IMMUNESUPPRESSANT RECEPTOR - The present invention relates to use of an antagonist of BIR1 (B cell immunoglobulin receptor 1) related to the present invention, a method for screening the antagonist, in addition to subtype polypeptides of BIR1, the polynucleotide encoding them and antibodies for the polypeptides. BIR1 functions as an immunosuppressive receptor, and the antagonist of BIR1 has immunopotentive activity, which is able to use for preventing and/or treating a cancer, an immunodeficiency disease or an infectious disease. | 2011-03-24 |
20110070237 | METHODS OF MODULATING AND IDENTIFYING AGENTS THAT MODULATE INTRACELLULAR CALCIUM - Methods are provided for identifying agents that modulate intracellular calcium. Also provided are methods of modulating calcium within cells and methods of identifying proteins involved in modulating intracellular calcium. | 2011-03-24 |
20110070238 | CYTOTOXIC ANTI-LAG-3 MONOCLONAL ANTIBODY AND ITS USE IN THE TREATMENT OR PREVENTION OF ORGAN TRANSPLANT REJECTION AND AUTOIMMUNE DISEASE - Cytotoxic anti-LAG-3 monoclonal antibodies or fragments thereof causing depletion of LAG-3 | 2011-03-24 |
20110070239 | ANTI-OX40L ANTIBODIES - This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C | 2011-03-24 |
20110070240 | METHODS OF TREATING B-CELL CANCERS - The present invention is directed to methods of causing malignant B-cells and treating malignant B-cells. These methods involve the use of an inhibitor of PKK activity, whether active directly against PKK or effective to knockdown PKK expression, which when introduced into a malignant B cell (or administered to a patient) is effective to cause cell death of the malignant B cell, thereby treating the B-cell malignancy. | 2011-03-24 |
20110070241 | METHODS FOR MODULATING IMMUNE RESPONSES TO AAV GENE THERAPY VECTORS - The present disclosure provides methods of inhibiting an immune response to a viral vector used in gene therapy, such as adeno-associated virus (AAV), which involves co-administration of viral vector and an interfering molecule. The interfering molecule functions by either disrupting the TLR9-MyD88-type I IFN signaling pathway and/or neutralizing Type I IFNs, thereby inhibiting the immune response directed against the viral vector. The methods additionally encompass the step of re-administering the viral vector. | 2011-03-24 |
20110070242 | Methods for Diagnosing and Treating Iron Dysregulation - The present invention relates to methods for diagnosing and treating iron overload and iron deficiency. | 2011-03-24 |
20110070243 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 2011-03-24 |
20110070244 | METHODS FOR THE TREATMENT OF MULTIPLE MYELOMA - Methods for treating multiple myeloma with inhibitors of CXCR4, such as AMD3100 and anti-CXCR4 antibodies, are described. The decreased expression of CXCR4 on multiple myeloma cells according to the invention results in decreased homing of the cells to the bone marrow and a reduction in the development of the disease. Also disclosed are pharmaceutical compositions incorporating such inhibitors for use in the therapeutic treatment of multiple myeloma. The treatment methods described herein can be used independently, or in conjunction with, other therapies for the treatment of multiple myeloma. | 2011-03-24 |
20110070245 | IMP-1 ONCOGENE AS A THERAPEUTIC TARGET AND PROGNOSTIC INDICATOR FOR LUNG CANCER - IMP-1 was abundantly expressed in the majority of lung-cancers examined. Positive immunostaining of IMP-1 was correlated with tumor size (pT-classification; P=0.0003), non-adenocarcinoma histology (P<0.0001), low-histological grade (P=0.0001), and poor prognosis (P=0.0053). Suppression of IMP-1 expression with siRNA effectively suppressed growth of NSCLC cells. IMP-1 was able to bind to mRNAs encoding a variety of proteins involved in signal transduction, cell-cycle progression, cell adhesion and cytoskeleton, and various types of enzymatic activities. These results suggest that IMP-1 expression is likely to play important roles in lung cancer development and progression, and that IMP-1 is a prognostic marker and a promising therapeutic target for treatment of lung cancer. | 2011-03-24 |
20110070246 | Antibodies Against CDCP1 for the Treatment of Cancer - The present invention relates to antibodies against human CDCP1 binding to the same epitope as CUB4 (Deposition No. DSM ACC2551) for the treatment of cancer. | 2011-03-24 |
20110070247 | PROTEIN MODULATORS - The present invention relates to modulators of the Neuregulin (NRG) family, particularly NRG1 and more particularly NRG1β, and most particularly NRG1β1. The present invention also relates to the use of such modulators to inhibit goblet cell hyperplasia and therefore also relates to the use of such modulators in the treatment or prevention of human diseases and disorders featuring pathological mucus production such as COPD, CF, chronic bronchitis and asthma. | 2011-03-24 |
20110070248 | DR5 LIGAND DRUG CONJUGATES - Ligand Drug Conjugates are provided having a DR5 binding moiety attached via linking groups and/or spacers to a therapeutic agent and are effective in treatment of various cancers. | 2011-03-24 |
20110070249 | IMMUNIZING COMPOSITION AND METHOD FOR INDUCING AN IMMUNE RESPONSE AGAINST THE Beta-SECRETASE CLEAVAGE SITE OF AMYLOID PRECURSOR PROTEIN - The present invention is directed to an immunizing composition containing an antigenic product such as a multiple antigen peptide system (MAPS) or a filamentous bacteriophage displaying an AβPP epitope spanning the β-secretase cleavage site of AβPP and a method for inducing an immune response against the β-secretase cleavage site of AβPP using this immunizing composition. The present invention is also directed to antibodies against the β-secretase cleavage site of AβPP and their use in a method for inhibiting the formation of amyloid β. | 2011-03-24 |
20110070250 | Therapeutical Composition Containing Dentritic Cells and use Thereof - The present invention relates to a method for the preparation of a therapeutical composition, in particular, the present invention relates to a method for treating dendritic cells with a combination of at least one interferon gamma receptor agonist and at least one toll like receptor 2 and/or TLR 6 agonist and using these pretreated dendritic cells for the preparation of a therapeutical composition. Moreover, the present invention relates to a therapeutical composition containing dendritic cells and the use thereof for the treatment of various diseases and disorders. | 2011-03-24 |
20110070251 | CANCER VACCINE COMPOSITION - A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof. | 2011-03-24 |
20110070252 | MAGE-A3/HPV 16 PEPTIDE VACCINES FOR HEAD AND NECK CANCER - The present invention relates to Trojan antigens, and immunogenic compositions comprising the Trojan antigens. The present invention also relates to methods of generating an immune response in a subject using the Trojan antigens or immunogenic compositions. The present invention further relates to methods of treating squamous cell carcinoma of the head and neck (SCCHN) using the Trojan antigens and immunogenic compositions of the present invention. | 2011-03-24 |
20110070253 | TUMOUR-ASSOCIATED PEPTIDES BINDING TO MHC MOLECULES - The invention relates to a tumour-associated peptide with an amino acid sequence that is selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 101 of the attached sequence protocol, wherein the peptide has the ability to bind to a molecule of the human major-histocompatibility-complex (MHC) class-I. In addition, the invention relates to the use of the peptides and the nucleic acids encoding for the peptides for the production of a medicament, and for the treatment of tumorous diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described that has at least one of the peptides. | 2011-03-24 |
20110070254 | MUTATIONS IN THE INFLUENZA A VIRUS NS1 GENE AND USE THEREOF - NS1 variant polypeptides, proteins or functional fragments thereof are described which have useful properties for increasing viral protein synthesis, IFN induction, and IFN resistance. The NS1 variant polypeptides, proteins or functional fragments comprise a substitution in the amino acid sequence of the wild type NS1 protein at a position corresponding to Asp-2, Val-23, Leu-98, Phe-103, Ser-103, Met-106, Met-124, Asp-125, Val-180, Val-226 or Arg-227, or combinations thereof expressed alone or in infectious virus. | 2011-03-24 |
20110070255 | IMMUNOGENIC PEPTIDE COMPOSITION FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE - The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of Alzheimer's Disease. More particularly, the peptide immunogen comprises a main functional/regulatory site, an N-terminal fragment of Amyloid β (Aβ) peptide linked to a helper T cell epitope (Th) having multiple class II MHC binding motifs. The peptide immunogen elicits a site-directed immune response against the main functional/regulatory site of the Aβ peptide and generate antibodies, which are highly cross-reactive to the soluble Aβ | 2011-03-24 |
20110070256 | Vaccine Antigens from Piscirickettsia Salmonis - The present invention discloses novel proteins, e.g., antigens, from | 2011-03-24 |
20110070257 | Polyvalent Chimeric OSPC Vaccinogen and Diagnostic Antigen - A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammalian | 2011-03-24 |
20110070258 | METHOD OF SLOWING THE AGING PROCESS BY ACTIVATING SIRTUIN ENZYMES - The fucoxanthin/pomegranate seed oil composition describes a method of slowing the aging process in a mammalian subject by activating at least one member of the sirtuin family of proteins, wherein the activating step includes administering to the subject a synergistic combination of fucoxanthin and punicic acid. Sirtuin enzymes exert their function by removing acetyl groups from proteins. The deacetylation results in inactivation of the proteins' role in cell metabolism and prevents genes from over-expression, thereby putting a cell into a state of hibernation and increasing its lifespan. | 2011-03-24 |
20110070259 | Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine - The present invention describes derivatized polysaccharide-protein conjugates, a composition comprising one or more of such derivatized polysaccharide-protein conjugates and methods of immunizing human patients with the same. The derivatized polysaccharide-protein conjugates are purified capsular polysaccharides from | 2011-03-24 |
20110070260 | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use - The invention provides immunogenic formulations comprising virus-like particles (VLPs) from two or more genoclusters and/or strains of norovirus in a pharmaceutically acceptable carrier. In representative embodiments, the formulation also comprises an adjuvant, for example, a viral adjuvant or CpG. The invention also provides methods of inducing an immune response to one or more noroviruses. | 2011-03-24 |
20110070261 | Combination Vaccines Against Mycobacterium SP. and Methods of Using the Same - The invention relates to a combination vaccine against | 2011-03-24 |
20110070262 | Viral Vectors and Their Use in Therapeutic Methods - The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease. | 2011-03-24 |
20110070263 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided. | 2011-03-24 |
20110070264 | RABIES VIRUS VECTOR SYSTEMS AND COMPOSITIONS AND METHODS THEREOF - Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions including ERA and/or ERA derivative strain viruses, nucleic acids and/or proteins. In some instances, the compositions are immunogenic compositions useful for the pre- or post-exposure treatment of Rabies Virus. | 2011-03-24 |
20110070265 | ENGINEERED PERTACTIN VARIANTS FOR VACCINE USE - The present invention is related with the field of Biomedicine. It comprises the engineering of the Pertactin protein (Prn) and using it as part of bacterial vaccines, and more precisely, as part of acellular vaccines against | 2011-03-24 |